Vice President Of Business Development
CurrentWe have formed a new gene therapy manufacturing CDMO called Advanced Medicine Partners. The new company is a spin out from Jaguar Gene Therapy. AMP is operated by an experienced gene therapy team of ~55 employees with extensive manufacturing, analytical development, and QC testing expertise from AveXis/Novartis and Jaguar Gene Therapy. AMP developed the Zolgensma® manufacturing process and analytics and were responsible for end-to-end global product approval and commercialization. This team also successfully filed a new IND for Jaguar where there were no CMC comments received. This team knows how to get products approved and has worked together for decades. AMP has a proven development platform and has developed a robust and reproducible AAV manufacturing process and has successfully run over 350 total batches at its facilities. AMP’s innovative process is among the most productive in the industry and consistently generates >95% functional full capsids. Our manufacturing process has received extremely positive feedback from multiple regulatory bodies as part of multiple gene therapy programs. AMP’s process sciences and analytical infrastructure is operational today and available to rapidly move your development programs forward. I am excited to say that I have joined the company as VP, Business Development.